Stockscreener 앱 받기
54.71
3.56%
1.88
시간 외 거래:
54.75
0.04
+0.07%
전일 마감가:
$52.83
열려 있는:
$53.18
하루 거래량:
1.67M
Relative Volume:
0.71
시가총액:
$8.58B
수익:
$1.17B
순이익/손실:
$150.71M
주가수익비율:
58.20
EPS:
0.94
순현금흐름:
$245.03M
1주 성능:
+9.71%
1개월 성능:
+1.05%
6개월 성능:
-18.06%
1년 성능:
-25.51%
1일 변동 폭
$52.92
$54.83
1주일 범위
$49.15
$54.83
52주 변동 폭
$46.01
$80.95
바이오-테크네 Stock (TECH) Company Profile
명칭
Bio Techne Corp
전화
(612) 379-8854
주소
614 MCKINLEY PL N E, MINNEAPOLIS, MN
TECH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TECH
Bio Techne Corp
|
54.71 | 8.28B | 1.17B | 150.71M | 245.03M | 0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
바이오-테크네 Stock (TECH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-22 | 재개 | Stephens | Overweight |
| 2025-07-09 | 개시 | TD Cowen | Buy |
| 2025-05-30 | 개시 | Wells Fargo | Overweight |
| 2025-04-09 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2025-03-18 | 개시 | Evercore ISI | Outperform |
| 2025-02-19 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-22 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-02-08 | 개시 | Scotiabank | Sector Outperform |
| 2024-02-02 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-12-07 | 개시 | UBS | Buy |
| 2023-08-28 | 개시 | William Blair | Outperform |
| 2023-01-10 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | 개시 | Deutsche Bank | Buy |
| 2022-12-12 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-12-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-04-25 | 다운그레이드 | Wells Fargo | Equal Weight → Underweight |
| 2021-09-15 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-08 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2021-02-23 | 업그레이드 | Stifel | Hold → Buy |
| 2021-01-25 | 재확인 | The Benchmark Company | Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | 개시 | Atlantic Equities | Overweight |
| 2020-07-15 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2020-05-27 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-05-14 | 개시 | The Benchmark Company | Buy |
| 2020-01-08 | 재개 | Stephens | Overweight |
| 2020-01-08 | 개시 | Wells Fargo | Equal Weight |
| 2020-01-07 | 개시 | Citigroup | Neutral |
| 2019-11-15 | 개시 | Stifel | Buy |
| 2019-07-02 | 업그레이드 | Janney | Neutral → Buy |
| 2019-01-14 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2018-10-31 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2018-10-17 | 개시 | Goldman | Neutral |
| 2018-06-15 | 개시 | Argus | Buy |
| 2017-07-13 | 개시 | Wells Fargo | Market Perform |
| 2017-02-09 | 개시 | Citigroup | Buy |
| 2017-01-18 | 개시 | Deutsche Bank | Buy |
| 2016-11-10 | 재개 | Leerink Partners | Outperform |
| 2015-01-21 | 재확인 | Robert W. Baird | Outperform |
| 2013-09-20 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
모두보기
바이오-테크네 주식(TECH)의 최신 뉴스
Alignment Healthcare, Bio-Techne, Envista, iRhythm, and UFP Technologies Shares Skyrocket, What You Need To Know - uk.finance.yahoo.com
Bio-Techne's Q4 2025: Navigating Contradictions in NIH Funding, China Growth, and Revenue Outlook - AInvest
The 5 Most Interesting Analyst Questions From Bio-Techne’s Q2 Earnings Call - Yahoo Finance
Revvity, Avantor, Azenta, Bio-Techne, and Amneal Shares Skyrocket, What You Need To Know - Yahoo Finance
TECH Q2 Deep Dive: Margin Pressures and Portfolio Shifts Amid Market Uncertainty - Yahoo Finance
Bio-Techne Leads Key Proteomic Reagent Markets, but Near-Term Challenges Loom - Morningstar
Bio-Techne Q4 Earnings Beat Estimates, Gross Margin Down, Stock Falls - MSN
Can Bio Techne Corporation disrupt its industryMaximum Leverage Stock Strategy - thegnnews.com
Bio-Techne Corp Q4 Earnings: Revenue Exceeds Estimates at $317M, Adjusted EPS Rises to $0.53, GAAP EPS Misses - AInvest
A Quick Look at Today's Ratings for Bio-Techne(TECH.US), With a Forecast Between $53 to $75 - 富途牛牛
Stocks making big moves yesterday: Bloomin' Brands, Bio-Techne, Snap, Grocery Outlet, and Paramount - Yahoo Finance
A Quick Look at Today's Ratings for Bio-Techne(TECH.US), With a Forecast Between $59 to $65 - 富途牛牛
Bio-Techne Corporation (NASDAQ:TECH) Q4 2025 Earnings Call Transcript - Insider Monkey
Bio-Techne Full Year 2025 Earnings: EPS Misses Expectations - Yahoo Finance
Bio-Techne (TECH) Q4 EPS Rises 8.2% - The Motley Fool
Bio-Techne takes a hit on Exodx sale to Mdxhealth - BioWorld MedTech
Bio-Techne Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Bio-Techne's Q4 Fiscal 2025 Results Trigger 6.5% Share DeclineNews and Statistics - IndexBox
Why Bio-Techne (TECH) Shares Are Plunging Today - Yahoo Finance
Earnings call transcript: Bio-Techne Q4 2025 beats EPS forecasts - Investing.com
Bio-Techne Q2 2025 Financial Results: Revenue and EPS Surpass ExpectationsNews and Statistics - IndexBox
Bio-Techne Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Bio-Techne (NASDAQ:TECH) Exceeds Q2 Expectations - Yahoo Finance
Here's What Key Metrics Tell Us About Techne (TECH) Q4 Earnings - Nasdaq
Bio-Techne Exceeds Forecasts And Refines Its Focus On Growth - Finimize
Bio-Techne Q4 25 Earnings Conference Call At 9:00 AM ET - Nasdaq
Techne (TECH) Beats Q4 Earnings and Revenue Estimates - Nasdaq
Bio-Techne Corp (TECH) Q4 Earnings: Revenue Surpasses Estimates - GuruFocus
Bio-Techne Posts Loss In Q4 - Nasdaq
Bio-Techne earnings beat by $0.03, revenue topped estimates - Investing.com Canada
Bio-techne declares quarterly dividend of $0.08 per share - Investing.com
Bio-techne declares quarterly dividend of $0.08 per share By Investing.com - Investing.com Canada
Bio-Techne Earnings Beat Estimates as Cell Therapy Division Drives Growth, Strategic Divestiture Announced - Stock Titan
Bio-Techne Releases Fourth Quarter Fiscal 2025 Results06.08.25News - Ariva
Bio-techne to sell exosome diagnostics business to mdxhealth By Investing.com - Investing.com South Africa
Bio-techne to sell exosome diagnostics business to mdxhealth - Investing.com
Bio-Techne Sells Prostate Cancer Test Business to Strengthen Core Operations: Strategic Shift Revealed - Stock Titan
Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne - The Manila Times
ScaleReady Announces a G-Rex® Grant has been awarded to Sidra Medicine - Yahoo Finance
Bio-Techne Q4 Earnings Preview: What's in Store for the Stock? - MSN
Will Volume Confirm Reversal in Bio Techne CorporationAI Based High Gain Watchlist Scanner Shared - metal.it
Stock Analysis | Bio-Techne OutlookWeak Technicals but Strong Fundamentals - AInvest
Earnings To Watch: Bio-Techne (TECH) Reports Q2 Results Tomorrow - Yahoo Finance
Why is Bio Techne Corporation stock attracting strong analyst attentionStay informed with daily expert analysis - Jammu Links News
What drives Bio Techne Corporation stock priceExponential wealth increase - Jammu Links News
When is Bio Techne Corporation stock expected to show significant growthGain insights from top financial experts - Jammu Links News
Is Bio Techne Corporation stock overvalued or undervaluedMassive profits - Jammu Links News
How strong is Bio Techne Corporation company’s balance sheetMaximize your returns with portfolio optimization - Jammu Links News
Bio Techne Corporation Shows Risk Reward Favoring UpsideAccurate Buy Point for Momentum Stocks Detected - beatles.ru
Is it the right time to buy Bio Techne Corporation stockAI Powered Growth Plan For 2025 - Jammu Links News
Bio-Techne Corporation (TECH) Slid on Weakness in Research Spending - Yahoo Finance
바이오-테크네 (TECH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.67%
자본화:
|
볼륨(24시간):